Suppr超能文献

慢性移植物抗宿主病。第二部分:疾病活动度分级与治疗管理。

Chronic graft-versus-host disease. Part II: Disease activity grading and therapeutic management.

作者信息

Baumrin Emily, Loren Alison W, Falk Sandy J, Mays Jacqueline W, Cowen Edward W

机构信息

Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania.

Blood and Marrow Transplant, Cell Therapy and Transplant Program, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Division of Hematology/Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

出版信息

J Am Acad Dermatol. 2024 Jan;90(1):19-36. doi: 10.1016/j.jaad.2022.12.023. Epub 2022 Dec 23.

Abstract

Chronic graft-versus-host disease (cGVHD) is a major complication of allogeneic hematopoietic cell transplantation and a leading cause of long-term morbidity, nonrelapse mortality, and impaired health-related quality of life. The skin is commonly affected and presents heterogeneously, making the role of dermatologists critical in both diagnosis and treatment. In addition, new clinical classification and grading schemes inform treatment algorithms, which now include 3 Federal Drug Administration-approved therapies, and evolving transplant techniques are changing disease epidemiology. Part I reviews the epidemiology, pathogenesis, clinical manifestations, and diagnosis of cGVHD. Part II discusses disease grading and therapeutic management.

摘要

慢性移植物抗宿主病(cGVHD)是异基因造血细胞移植的主要并发症,也是导致长期发病、非复发死亡率及健康相关生活质量受损的主要原因。皮肤是常见的受累部位,表现多样,这使得皮肤科医生在诊断和治疗中发挥着关键作用。此外,新的临床分类和分级方案为治疗算法提供了依据,目前治疗算法包括3种美国食品药品监督管理局批准的疗法,并且不断发展的移植技术正在改变疾病的流行病学。第一部分回顾了cGVHD的流行病学、发病机制、临床表现及诊断。第二部分讨论疾病分级及治疗管理。

相似文献

1
Chronic graft-versus-host disease. Part II: Disease activity grading and therapeutic management.
J Am Acad Dermatol. 2024 Jan;90(1):19-36. doi: 10.1016/j.jaad.2022.12.023. Epub 2022 Dec 23.
2
Chronic graft-versus-host disease. Part I: Epidemiology, pathogenesis, and clinical manifestations.
J Am Acad Dermatol. 2024 Jan;90(1):1-16. doi: 10.1016/j.jaad.2022.12.024. Epub 2022 Dec 23.
3
Cutaneous Chronic Graft-Versus-Host Disease: Clinical Manifestations, Diagnosis, Management, and Supportive Care.
Transplant Cell Ther. 2024 Sep;30(9S):S513-S533. doi: 10.1016/j.jtct.2024.05.020.
4
Chronic graft-versus-host disease in pediatric patients: Differences and challenges.
Blood Rev. 2023 Jul;60:101054. doi: 10.1016/j.blre.2023.101054. Epub 2023 Feb 8.
6
Recent advances and research progress in biomarkers for chronic graft versus host disease.
Crit Rev Oncol Hematol. 2023 Jun;186:103993. doi: 10.1016/j.critrevonc.2023.103993. Epub 2023 Apr 13.
7
[Pathogenesis and Therapeutic Prospects of Chronic Graft-Versus-Host Disease --Review].
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2024 Apr;32(2):647-652. doi: 10.19746/j.cnki.issn.1009-2137.2024.02.050.
9
[Chronic graft-versus-host disease].
Tidsskr Nor Laegeforen. 2023 Mar 13;143(4). doi: 10.4045/tidsskr.22.0525. Print 2023 Mar 14.
10
Impact of Center Volume on Chronic Graft Versus Host Disease in Patients With Allogeneic Stem Cell Transplantation.
Transplant Cell Ther. 2024 Mar;30(3):326.e1-326.e14. doi: 10.1016/j.jtct.2024.01.056. Epub 2024 Jan 11.

引用本文的文献

2
Combination treatment of extracorporeal photopheresis and belumosudil for chronic graft-versus-host disease.
Arch Dermatol Res. 2025 Jan 20;317(1):298. doi: 10.1007/s00403-024-03770-y.
3
Cutaneous Chronic Graft-Versus-Host Disease: Clinical Manifestations, Diagnosis, Management, and Supportive Care.
Transplant Cell Ther. 2024 Sep;30(9S):S513-S533. doi: 10.1016/j.jtct.2024.05.020.
5
Role of extracorporeal photopheresis in the management of acute and chronic graft versus disease: current status.
Bone Marrow Transplant. 2024 Sep;59(9):1209-1214. doi: 10.1038/s41409-024-02360-w. Epub 2024 Jul 3.

本文引用的文献

1
Results of Multicenter Phase II Study With Imatinib Mesylate in Allogeneic Recipients With Steroid-Refractory Chronic GVHD.
Cell Transplant. 2022 Jan-Dec;31:9636897221113789. doi: 10.1177/09636897221113789.
4
T Helper Cell Lineage-Defining Transcription Factors: Potent Targets for Specific GVHD Therapy?
Front Immunol. 2022 Jan 5;12:806529. doi: 10.3389/fimmu.2021.806529. eCollection 2021.
7
Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease.
N Engl J Med. 2021 Jul 15;385(3):228-238. doi: 10.1056/NEJMoa2033122.
8
Methods to Assess Disease Activity and Severity in Cutaneous Chronic Graft-versus-Host Disease: A Critical Literature Review.
Transplant Cell Ther. 2021 Sep;27(9):738-746. doi: 10.1016/j.jtct.2021.05.030. Epub 2021 Jun 6.
9
ROCK2 Inhibition With Belumosudil (KD025) for the Treatment of Chronic Graft-Versus-Host Disease.
J Clin Oncol. 2021 Jun 10;39(17):1888-1898. doi: 10.1200/JCO.20.02754. Epub 2021 Apr 20.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验